Please login to the form below

Not currently logged in

neurodegenerative diseases

This page shows the latest neurodegenerative diseases news and features for those working in and with pharma, biotech and healthcare.

FDA expecting boom in cell and gene therapies

FDA expecting boom in cell and gene therapies

It intends to make “maximum use” of expedited regulatory pathways, including the regenerative medicine advanced therapy (RMAT) designation and accelerated approval, particularly for products that offer potential cures for diseases with

Latest news

More from news
Approximately 3 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s. ... Target early disease stages: It is probably true for all neurodegenerative diseases that symptoms

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Denali had also been busy having completed a $250m IPO in early December.  The company has a focus in neurodegenerative diseases and a technology,

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business. ... These deals were mainly early stage deals in the areas of

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for

  • Deal Watch November 2016 Deal Watch November 2016

    equity investment, 2 year collaboration. 145. Chase Pharmaceuticals/ Allergan. fixed dose combinations for Alzheimer's and other neurodegenerative diseases inc CPC-201 (donepezil). ... acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....